Last updated: 23 January 2018 at 11:46pm EST

Llc Cvf, Net Worth




The estimated Net Worth of Llc Cvf, is at least $2.06 Milione dollars as of 5 July 2017. Llc Cvf owns over 180,000 units of Aileron Therapeutics Inc stock worth over $2,062,598 and over the last 7 years Llc sold ALRN stock worth over $0.

Llc Cvf ALRN stock SEC Form 4 insiders trading

Llc has made over 1 trades of the Aileron Therapeutics Inc stock since 2017, according to the Form 4 filled with the SEC. Most recently Llc bought 180,000 units of ALRN stock worth $2,700,000 on 5 July 2017.

The largest trade Llc's ever made was buying 180,000 units of Aileron Therapeutics Inc stock on 5 July 2017 worth over $2,700,000. On average, Llc trades about 180,000 units every 0 days since 2017. As of 5 July 2017 Llc still owns at least 716,180 units of Aileron Therapeutics Inc stock.

You can see the complete history of Llc Cvf stock trades at the bottom of the page.



What's Llc Cvf's mailing address?

Llc's mailing address filed with the SEC is 222 N LaSalle Dr #2000, Chicago, IL 60601, USA.

Insiders trading at Aileron Therapeutics Inc

Over the last 14 years, insiders at Aileron Therapeutics Inc have traded over $6,473,296 worth of Aileron Therapeutics Inc stock and bought 16,658,005 units worth $51,661,886 . The most active insiders traders include Muneer A Satter, Bioventures Ltd Novartis Ag... e Armen Shanafelt. On average, Aileron Therapeutics Inc executives and independent directors trade stock every 77 days with the average trade being worth of $908,853. The most recent stock trade was executed by Of Texas/Texas Am Investmen... on 14 June 2024, trading 6,607 units of ALRN stock currently worth $21,539.



What does Aileron Therapeutics Inc do?

aileron is the clinical-stage leader in the field of stapled peptide therapeutics for cancers and other diseases. our lead product candidate, alrn-6924, which is being evaluated in multiple clinical trials, reactivates p53-mediated tumor suppression by targeting both of the primary p53 suppressor proteins mdmx and mdm2. the p53 protein, often referred to as the “guardian of the genome,” is known for its central role in preventing cancer initiation and progression, and its inactivation is essential for the formation of virtually all cancers. we believe that alrn-6924 is the first and only product candidate in clinical development that can inhibit both mdmx and mdm2, which we believe, based on published data and our preliminary clinical results, are equally important in restoring p53 function as the body’s first line of defense against cancer. based on preclinical data and preliminary evidence of safety and anti-tumor activity in our ongoing clinical trials, we believe there may be a sig



What does Aileron Therapeutics Inc's logo look like?

Aileron Therapeutics Inc logo

Complete history of Llc Cvf stock trades at Aileron Therapeutics Inc

Data
#
Ditta
Persona
Trans.
Transazione
Azioni Prezzo per azione Prezzo totale Azioni dopo Fonte
5 Jul 2017 Llc Cvf,
10% proprietario
Acquistare 180,000 $15.00 $2,700,000
5 Jul 2017
716,180


Aileron Therapeutics Inc executives and stock owners

Aileron Therapeutics Inc executives and other stock owners filed with the SEC include: